Article
HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jul 2020
Shim J H, Kim H S, Cha H, Kim S, Kim T M, Anagnostou V, Choi Y-L, Jung H A, Sun J-M, Ahn J S, Ahn M-J, Park K, Park W-Y, Lee S-H
Abstract excerpt
BACKGROUND: Immune checkpoint inhibitors (ICIs) have been shown to be beneficial for some patients with advanced non-small-cell lung cancer (NSCLC). However, the underlying mechanisms mediating the limited response to ICIs remain unclear. PATIENTS AND METHODS: We carried out whole-exome sequencing on 198 advanced NSCLC tumors that had been sampled before anti-programmed cell death 1 (anti-PD-1)/programmed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.